$0.59
39.68%
Nasdaq, Fri, Sep 18 2026.
ISIN
US68619K2042
Symbol
ORGS

Orgenesis Inc. Stock price

$0.59
+0.29 96.67% 1M
+0.34 136.00% 6M
+0.44 293.33% YTD
+0.54 1,056.86% 1Y
-6.60 91.79% 3Y
-48.61 98.80% 5Y
-49.21 98.82% 10Y
+0.21 56.46% 20Y
Nasdaq, Closing price Fri, Sep 18 2026
+0.17 39.68%
ISIN
US68619K2042
Symbol
ORGS
Industry

Is Orgenesis Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.

Key metrics

Basic
Market capitalization
$5.8m
Enterprise Value
$22.4m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative
P/S
5.6 | -
EV/Sales
21.6 | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-2,775.8%
Return on Equity
128.4%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
1.3%
Employees
146
Rev per Employee
$10.0k

Orgenesis Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Orgenesis Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Orgenesis Inc. forecast:

Buy
86%
Hold
14%

Financial data from Orgenesis Inc.

Dec '24
+/-
%
1.04 1.04
93% 93%
100%
- Direct Costs 1.93 1.93
69% 69%
186%
-0.89 -0.89
111% 111%
-86%
- Selling and Administrative Expenses 13 13
26% 26%
1,244%
- Research and Development Expense 12 12
10% 10%
1,171%
-20 -20
54% 54%
-1,922%
- Depreciation and Amortization 1.43 1.43
32% 32%
138%
EBIT (Operating Income) EBIT -21 -21
52% 52%
-2,060%
Net Profit -48 -48
75% 75%
-4,632%

In millions USD.

Don't miss a Thing! We will send you all news about Orgenesis Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment through MaSTherCell, comprises of services from cell therapy development through cell therapy manufacturing for and companies that provide end-to-end solution. The POC segment provides multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Head office United States
CEO Ms. Caplan
Employees 146
Founded 2008
Website www.orgenesis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today